PubMed Health⌕ Search

Biomedical subjects

S S Boĭko

Publications and source records attributed to S S Boĭko.

At least 37 records · Page 2Linked to original sources
PubMedDate not supplied

[Experimental and clinical data on the ability of bemetil to penetrate the hemato-encephalic barrier].

Experimental and clinical data indicated bemetil ability to penetrate through the blood-brain barrier. Bemetil concentration in the rat brain tissue was found to be significantly higher than in the plasma. Its concentration in the cerebrospinal fluid of patients with craniocerebral trauma was lower than in the plasma; the latter however does not exclude the possibility of bemetil accumulation in the brain structures.

Animals↗
PubMedDate not supplied

[Bemetil pharmacokinetics in an experiment on rats].

Pharmacokinetics of bemetil (2-ethyl-mercaptobenzimidazole), a representative of the group of actoprotectors, was studied at intravenous and intragastric administration during the experiment on rats by using gas-liquid chromatography. It was found that at intragastric administration the drug rapidly appeared in the systemic circulation, reached the maximal concentration in one hour; the character of bemetil elimination from the blood was biexponential at both routes of administration. The two-compartment model was used for calculation of the main pharmacokinetic constants and bioavailability. The analysis of the experimental findings on urinary excretion of bemetil made it possible to conclude that little amount of the drug (0.56%) is excreted in the urine in the unchanged form; most amount of bemetil is excreted in the form of metabolites and in the bound state.

Administration, Oral↗
PubMedDate not supplied

[Pharmacokinetics and the clinical effect of bemitil after a single administration].

It was found on studying a novel psychotropic drug bemitil that after its single administration kinetic curves significantly differed depending on a clinical effect of the test dose in patients with asthenic states. At predomination of the psychoactivating component of action one could note a larger area under the concentration-time relationship curve and a shorter period of half-excretion than in patients with the tranquilizing action. The obtained data on the difference in the drug test dose effect depending on the drug pharmacokinetics should be taken into consideration at determination of bemitil course therapy duration in patients with neuroses and neurosis-like states with predominance of asthenic disturbances in the clinical picture.

Adult↗
PubMedDate not supplied

[Nonachlazine in solution as an arresting agent in stenocardiac attacks].

Nonachlazine infused in the form of a solution penetrates rapidly the blood and organs. In experiments on cats it was shown that infusion of the drug into the stomach enriches the speed of blood flow and oxyhemoglobin amount in the coronary sinus blood after 2--3 minutes. Heart oxygen consumption increases slightly. Nonachlazine solution is little toxic. As a result of pharmacological research it is recommended for removing angina pectoris attacks in patients irresponsive to nitroglycerin.

Angina Pectoris↗
PubMedDate not supplied

[Effect of phenazepam on the body organs and systems of rats subjected to prolonged ethanol exposure].

Experiments made on 80 randombred male rats have demonstrated that the tranquilizer phenazepam in a daily dose of 1 mg/kg administered per os to intact animals for 14 days produces no adverse changes in the hematological, biochemical and morphological indicators that characterize the status of the most important organs and systems of the body. Administration of phenazepam to rats preexposed to ethanol (4 g/kg per os once a day for a month) has been found to retard the elimination of morphological alterations in the liver and brain induced by ethanol. The results obtained allow recommending the use of appropriate experimental models in the preclinical study of the safety of new antialcoholic agents.

Alcoholism↗
PubMedDate not supplied

[Pharmacokinetic study of 2-(N-benzylamino)adamatane (bemantan) by a gas-liquid chromatographic method].

The pharmacokinetics of bemantan 2-(N-benzylamino)adamantane was studied in rat experiments by gas liquid chromatography after the drug was administered in a single dose per os or intraperitoneally. It has been shown that the drug per os is rapidly absorbed by the blood and enters the viscera, readily penetrates the blood-brain barrier. Intraperitoneal administration of the drug in the form of a starch suspension delays the attainment of the maximum drug blood level. With both routes of administration the drug rapidly disappears from the blood and organs. Small amounts of the unchanged drug are excreted in bound and free forms with urine. Rapid disappearance of the drug from the blood and organs is likely to be accounted for by its intensive metabolism, but the formation of conjugated metabolites and their binding to tissue structures.

Adamantane↗
PubMedDate not supplied

[Effect of a physical load on the toxicological characteristics of sodium oxybutyrate].

Toxicity of sodium hydroxybutyrate administered for a long time was studied in freely moving animals and in those exposed to intense exercise (daily swimming for 30 min). Hematological, biochemical and morphological analyses demonstrated the drug to be little toxic. Intense exercise did not entail the increased toxicity of sodium hydroxybutyrate. On the contrary, the biochemical parameters (the content of creatinine, protein and protein fractions) altered by exercise returned to normal as a result of a prolonged administration of the drug.

Animals↗
PubMedDate not supplied

[Interspecific differences in kemantan pharmacokinetics].

The pharmacokinetics of the new immunostimulant kemantane, adamantane derivative, used in two species of animals (rats and rabbits) and man was studied. There were significant differences in the pharmacokinetics of kemantane and its active metabolite--adamantane-1,4-diol between the species.

Adamantane↗
PubMedDate not supplied

[The transplacental transport and effect of morphine administered in the prenatal period on its level in adult rats].

The morphine concentration in the placenta, plasma of pregnant rats and their fetuses and in the plasma of prenatally morphinized rats was determined with HPLC method. It was found that 10 min after the intraperitoneal morphine administration at a dose of 20 mg/kg the morphine concentration in the fetus blood plasma is 3 times as large and in the placenta is 2 times as large as in the blood plasma of pregnant rats. The morphine level in prenatally morphinized rats was reliably higher than that in the control animals.

Animals↗
PubMedDate not supplied

[The use of the HPLC method for the quantitative determination of a peptide analog of piracetam with nootropic activity and its main metabolites].

HPLC method has been developed for pharmacokinetic study of nootropic peptide analog of pyracetam GVS-111 and its main metabolites. In the model experiments on rats the enzymes of blood plasma were shown to metabolize GVS-111 during 1-h incubation with the formation of metabolite, phenylacetylproline. This suggests that in vivo experiments these blood plasma enzymes will also be actively involved in the metabolism of the compound tested. The liver tissue enzymes metabolized GVS-111 much slower.

Animals↗
PubMedDate not supplied

[The pharmacokinetics of the dipeptide analog of piracetam with nootropic activity GVS-111 and of its basic metabolites].

The pharmacokinetics of a new nootropic dipeptide analog of piracetam-N-phenylacetyl-L-prolylglycine (GWS-111) and its main metabolites were studied in rats by means of high performance liquid chromatography and gas-liquid chromatography. The compound under study showed a greater resistance to an enzymatic effect than natural neuropeptides. In addition to an unchanged compound three of its metabolites were found in the blood plasma of the rats. One of them, cyclo-Pro-Gly was an active metabolite of GWS-111.

Animals↗